Literature DB >> 29378134

Toll-like Receptor Agonist Conjugation: A Chemical Perspective.

Bob J Ignacio1, Tyler J Albin2, Aaron P Esser-Kahn2,3, Martijn Verdoes1.   

Abstract

Toll-like receptors (TLRs) are vital elements of the mammalian immune system that function by recognizing pathogen-associated molecular patterns (PAMPs), bridging innate and adaptive immunity. They have become a prominent therapeutic target for the treatment of infectious diseases, cancer, and allergies, with many TLR agonists currently in clinical trials or approved as immunostimulants. Numerous studies have shown that conjugation of TLR agonists to other molecules can beneficially influence their potency, toxicity, pharmacokinetics, or function. The functional properties of TLR agonist conjugates, however, are highly dependent on the ligation strategy employed. Here, we review the chemical structural requirements for effective functional TLR agonist conjugation. In addition, we provide similar analysis for those that have yet to be conjugated. Moreover, we discuss applications of covalent TLR agonist conjugation and their implications for clinical use.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29378134     DOI: 10.1021/acs.bioconjchem.7b00808

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  26 in total

1.  Potent and Prolonged Innate Immune Activation by Enzyme-Responsive Imidazoquinoline TLR7/8 Agonist Prodrug Vesicles.

Authors:  Bi Wang; Simon Van Herck; Yong Chen; Xiangyang Bai; Zifu Zhong; Kim Deswarte; Bart N Lambrecht; Niek N Sanders; Stefan Lienenklaus; Hans W Scheeren; Sunil A David; Fabian Kiessling; Twan Lammers; Bruno G De Geest; Yang Shi
Journal:  J Am Chem Soc       Date:  2020-06-30       Impact factor: 15.419

2.  Current Prospects in Peptide-Based Subunit Nanovaccines.

Authors:  Prashamsa Koirala; Sahra Bashiri; Istvan Toth; Mariusz Skwarczynski
Journal:  Methods Mol Biol       Date:  2022

3.  Next-Generation Diprovocims with Potent Human and Murine TLR1/TLR2 Agonist Activity That Activate the Innate and Adaptive Immune Response.

Authors:  Ming-Hsiu Yang; Jamie L Russell; Yuto Mifune; Ying Wang; Hexin Shi; Eva Marie Y Moresco; Daniel J Siegwart; Bruce Beutler; Dale L Boger
Journal:  J Med Chem       Date:  2022-06-29       Impact factor: 8.039

4.  Stereoisomeric Pam2CS based TLR2 agonists: synthesis, structural modelling and activity as vaccine adjuvants.

Authors:  Arshpreet Kaur; Sakshi Piplani; Deepender Kaushik; Johnson Fung; Isaac G Sakala; Yoshikazu Honda-Okubo; Surinder K Mehta; Nikolai Petrovsky; Deepak B Salunke
Journal:  RSC Med Chem       Date:  2022-04-20

Review 5.  The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy.

Authors:  Lingling Huang; Xiaoyan Ge; Yang Liu; Hui Li; Zhiyue Zhang
Journal:  Pharmaceutics       Date:  2022-06-10       Impact factor: 6.525

6.  Structure-Activity Relationship Studies To Identify Affinity Probes in Bis-aryl Sulfonamides That Prolong Immune Stimuli.

Authors:  Michael Chan; Fitzgerald S Lao; Paul J Chu; Jonathan Shpigelman; Shiyin Yao; Jason Nan; Fumi Sato-Kaneko; Vicky Li; Tomoko Hayashi; Maripat Corr; Dennis A Carson; Howard B Cottam; Nikunj M Shukla
Journal:  J Med Chem       Date:  2019-10-25       Impact factor: 7.446

7.  Photochemical Treatment of Drosophila APCs Can Eliminate Associated Viruses and Maintain the APC Function for Generating Antigen-Specific CTLs Ex Vivo.

Authors:  Jun Ye; Chunxia Yang; Zeling Cai; Weixing Shi; Hong Yu
Journal:  Mediators Inflamm       Date:  2018-09-20       Impact factor: 4.711

Review 8.  Molecular Repolarisation of Tumour-Associated Macrophages.

Authors:  Floris J van Dalen; Marleen H M E van Stevendaal; Felix L Fennemann; Martijn Verdoes; Olga Ilina
Journal:  Molecules       Date:  2018-12-20       Impact factor: 4.411

9.  Toll-Like Receptors (TLRs) Expression in Contracted Capsules Compared to Uncontracted Capsules.

Authors:  Y Bachour; M J P F Ritt; R Heijmans; F B Niessen; S P Verweij
Journal:  Aesthetic Plast Surg       Date:  2019-04-01       Impact factor: 2.326

Review 10.  Recent Advances in Toll Like Receptor-Targeting Glycoconjugate Vaccines.

Authors:  Qingjiang Li; Zhongwu Guo
Journal:  Molecules       Date:  2018-06-29       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.